ArticleBMC veterinary research2026
Canine epidermal growth factor-expressing Lactococcus lactis promotes intestinal injury repair and alleviates diarrhea in canine.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCanine diarrhea with long course and a certain mortality rate depends mainly on supportive treatment. Oral recombinant epidermal growth factor (EGF) can stimulate intestinal development and reduce diarrhea incidence in human and other animals, but few related studies have been done in canine.
resultsHere, we firstly constructed a recombinant lactococcus lactis (L. lactis) expressing bioactive canine EGF (cEGF), and then explored its effect on cell proliferation, intestinal injury repair and inflammatory factor secretion in diarrheal mice and canines. The results showed that cEGF promoted the proliferation of CMT-1211 cells, that cEGF-expressing L. lactis strain recovered the damaged mucous structure and suppressed the inflammatory response, potentially by activating EGF receptor and its downstream AKT and ERK1/2 signals, thereby alleviating diarrhea in mice and canine.
conclusionsWe first generated a cEGF-expressing L. lactis strain and demonstrated its potential to repair intestinal injury and alleviate diarrhea in mice and canines, and thus cEGF-expressing L. lactis could be a new therapy strategy for animal diarrhea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.